CI

At a glance

ClinicalIndex Comparison Record
N/AUnknown· 72 target
Drug / intervention
0.5% Ropivacaine +1 moredrug
Likely dose
0.5% Ropivacaine 20mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06145945
NCT06145945N/AUnknown

A Randomized Controlled Study of the Effect of Intraperitoneal Ropivacaine on Visceral Pain After Laparoscopic Gastrectomy

SanQing Jin·interventional·Posted Nov 24, 2023·Updated Nov 28, 2023

In Brief

A clinical study evaluating 0.5% Ropivacaine and Saline for Laparoscopic Gastrectomy and Ropivacaine. Targeting 72 participants across 1 site.

Detailed Summary

Visceral pain is obvious and lasts for a long time in patients after laparoscopic gastrectomy.Relieving the visceral pain is of great significance for patients' postoperative emotional experience, functional recovery and reducing the formation of long-term chronic pain. However, there is no clear clinical consensus on relieving visceral pain by now, so effective clinical methods to relieve visceral pain need to be explored urgently. Intraperitoneal spraying local anesthetics is a simple and inexpensive method, which has been proved to be safe and effective in randomized controlled trials and Meta-analysis of various types of surgery.However, its effect in clinical research is still controversial and many studies lack evaluation of postoperative recovery quality, so it has not been widely used in clinical practice. This study aims to explore the effect of intraperitoneal spraying ropivacaine (long-acting amide local anesthetic) on visceral pain after laparoscopic gastrectomy, and to systematically evaluate its effect on the recovery of gastrointestinal function and the inflammatory factors (IL-6, TNF-α) in abdominal drainage fluid.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--

Timeline

N/AUnknownOverdue
202420252026
First PostedNov 24, 2023
Enrollment StartNov 25, 2023
Primary CompletionMar 3, 2024
Study CompletionJul 7, 2024
TodayJul 1, 2026
Enrollment to primary: 3 monthsPosted 2.6 years ago

Interventions

0.5% Ropivacainedrug

20ml 0.5% ropivacaine is sprayed intraperitoneally

Salinedrug

20ml saline is sprayed intraperitoneally